- Home
- VERV vs SANA Comparison
VERV vs SANA Comparison
Compare VERV & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- SANA
- Stock Information
- Founded
- VERV 2018
- SANA 2018
- Country
- VERV United States
- SANA United States
- Employees
- VERV N/A
- SANA N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- SANA Medicinal Chemicals and Botanical Products
- Sector
- VERV Health Care
- SANA Health Care
- Exchange
- VERV Nasdaq
- SANA Nasdaq
- Market Cap
- VERV 475.0M
- SANA 522.4M
- IPO Year
- VERV 2021
- SANA 2021
- Fundamental
- Price
- VERV $7.28
- SANA $3.01
- Analyst Decision
- VERV Strong Buy
- SANA Strong Buy
- Analyst Count
- VERV 4
- SANA 4
- Target Price
- VERV $25.75
- SANA $13.00
- AVG Volume (30 Days)
- VERV 1.3M
- SANA 3.3M
- Earning Date
- VERV 02-28-2025
- SANA 03-07-2025
- Dividend Yield
- VERV N/A
- SANA N/A
- EPS Growth
- VERV N/A
- SANA N/A
- EPS
- VERV N/A
- SANA N/A
- Revenue
- VERV $24,396,000.00
- SANA N/A
- Revenue This Year
- VERV $106.46
- SANA N/A
- Revenue Next Year
- VERV N/A
- SANA N/A
- P/E Ratio
- VERV N/A
- SANA N/A
- Revenue Growth
- VERV 219.91
- SANA N/A
- 52 Week Low
- VERV $4.31
- SANA $1.52
- 52 Week High
- VERV $19.34
- SANA $12.00
- Technical
- Relative Strength Index (RSI)
- VERV 47.08
- SANA 50.21
- Support Level
- VERV $7.44
- SANA $3.00
- Resistance Level
- VERV $9.31
- SANA $3.35
- Average True Range (ATR)
- VERV 0.67
- SANA 0.24
- MACD
- VERV -0.12
- SANA -0.03
- Stochastic Oscillator
- VERV 14.01
- SANA 50.57
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.